Innovation
Professor Dame Sally Davies: Ten Years of the NIHR: Achievements and Challenges for the Next Decade
15 June 2017
In November 2016 Professor Dame Sally Davies delivered the 23rd OHE Annual Lecture on the topic of: Ten Years of the NIHR: Achievements and Challenges for…
Assessing the Value of New Antibiotics: Additional Elements of Value for Health Technology Assessment Decisions
30 May 2017
Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers…
New Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
22 May 2017
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This…
Incentives for New Drugs and Vaccines to Tackle Anti-Microbial Resistance
16 May 2017
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as…
New Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
7 March 2017
Just published is a new report entitled: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value. The publication is a report of the…
New Publication: Assessing Evidence and Access Associated with NICE HTA Decisions Categorised as “Recommended in Line with Clinical Practice”
6 January 2017
A new OHE Research Paper assesses the nature of evidence used to reach HTA decisions which NICE have classified as “Recommended in Line with Clinical Practice”…
New Report Published: Improving Efficiency and Resource Allocation in Future Cancer Care
26 September 2016
The Office of Health Economics (OHE) and the Swedish Institute for Health Economics (IHE) publish a report evaluating the efficiency of resource allocation in cancer care…
New Publication: Headroom Approach to Device Development
23 February 2016
OHE’s Amanda Cole co-authors a new publication on the headroom approach, which can help assess the commercial value and viability of medical device development.
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.